Shares of ResMed Slip 1.56% Despite Mixed Trading in S&P 500
June 25, 2023
☀️Trending News
RESMED ($NYSE:RMD): Shares of ResMed Inc., a leading medical technology company, slipped 1.56% to $216.97 on Thursday despite mixed trading in the S&P 500. ResMed Inc.’s stock has been positively correlated with the S&P 500 and as a result, the market’s relatively flat performance could be attributed to the company’s decreased stock price. ResMed Inc. is a leading innovator in the sleep and respiratory medical device industry. The company provides solutions to help people treat their sleep and breathing disorders, and their products are designed to improve patient quality of life, reduce the impact of chronic disease, and save healthcare costs.
ResMed Inc. manufactures and sells products such as sleep apnea machines and air solutions, portable oxygen concentrators, home sleep testing, and cloud software solutions for sleep management and respiratory care. The company has seen strong success over the past few years due to its innovative products and services, but the share price of ResMed Inc. slipped 1.56% on Thursday despite mixed trading in the S&P 500. Investors are likely keeping an eye on the company to see if its stock will recover in the near future.
Analysis
At GoodWhale, we conducted an analysis of RESMED INC‘s fundamentals to create a comprehensive view of the company. We rated RESMED INC as a medium risk investment, based on a combination of financial and business aspects. It’s important to note that we have identified one risk warning in the balance sheet – if you’re interested in finding out more about this, be sure to register with us! We pride ourselves in being able to provide in-depth insights into a company’s financial health, so you can make informed decisions when it comes to investing. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Resmed Inc. More…
| Total Revenues | Net Income | Net Margin |
| 4.02k | 862.95 | 21.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Resmed Inc. More…
| Operations | Investing | Financing |
| 535.35 | -1.17k | 668.96 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Resmed Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.71k | 2.78k | 26.77 |
Key Ratios Snapshot
Some of the financial key ratios for Resmed Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.6% | 14.0% | 27.9% |
| FCF Margin | ROE | ROA |
| 10.2% | 18.3% | 10.4% |
Peers
ResMed’s competitors include Natus Medical Inc, Sanara MedTech Inc, and Avita Corp.
– Natus Medical Inc ($NASDAQ:SMTI)
As of 2022, Sanara MedTech Inc has a market cap of 227.36M and a Return on Equity of -22.91%. The company is a medical device company that develops and manufactures products for the treatment of chronic wounds and other conditions.
– Sanara MedTech Inc ($TPEX:4735)
Avita Corp is a biotechnology company that develops, manufactures, and markets products based on regenerative medicine. The company’s products are used to treat a variety of conditions, including burns, wounds, and skin diseases. Avita’s products are sold in over 30 countries worldwide. The company has a market cap of 1.21B as of 2022 and a return on equity of 9.62%.
Summary
Investors in ResMed Inc. faced mixed results on Thursday, as shares of the company dropped 1.56% to $216.97. Analysts remain optimistic about ResMed Inc., projecting strong returns for investors in the near future. Investors should carefully consider the potential risks and rewards of investing in ResMed Inc., including potential market volatility and long-term growth potential.
Related Posts
Recent Posts
